Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.